# Endo Cvd Risk Assessment Cured Cushing General Population

> The guideline recommends that cardiovascular risk assessment and management in adults with cured Cushing syndrome follow the same approach as in the general population. Clinical triggers include evaluating a patient with cured Cushing syndrome, performing post-treatment cardiovascular risk assessment in Cushing, and planning long-term follow-up for cured endocrine disorders.

- Skill: `dromlakhani/endo-cvd-risk-assessment-cured-cushing-general-population` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-cvd-risk-assessment-cured-cushing-general-population`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-cvd-risk-assessment-cured-cushing-general-population/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-cvd-risk-assessment-cured-cushing-general-population

---


# Cardiovascular risk assessment and treatment approach same as general population for cured Cushing syndrome

## STEP 1 — Gather Information
Collect traditional risk factors (age, sex, smoking status, systolic blood pressure, antihypertensive use, total cholesterol, HDL-C, diabetes status) and calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations.

## STEP 2 — Rule In / Rule Out
If 10-year ASCVD risk is ≥20%, classify as high risk and recommend high-intensity statin therapy; if risk is <20%, proceed to further stratification.

## STEP 3 — Classify or Stratify
For risk <20%, categorize as low (<5%), borderline (5–7.4%), or intermediate (7.5–19.9%) and assess for risk-enhancing factors (e.g., family history of premature ASCVD, LDL‑C ≥160 mg/dL, metabolic syndrome, chronic kidney disease, lipoprotein(a) ≥50 mg/dL).

## STEP 4 — Decide
Low risk (<5%): advise lifestyle modification only. Borderline risk (5–7.4%): if risk‑enhancing factors are present, discuss statin initiation; if coronary artery calcium (CAC) score is zero, may favor withholding statin. Intermediate risk (7.5–19.9%): discuss moderate‑ or high‑intensity statin based on risk‑enhancing factors and patient preference. High risk already addressed in Step 2.

## Clinical Guardrails / Mimics / Pitfalls
Do not assume cured Cushing syndrome automatically warrants different CV risk assessment; do not omit traditional risk factor evaluation; avoid overtreating based on presumed endocrine‑related risk without calculation; do not neglect lifestyle modifications; reassess for disease recurrence if symptoms return.

## Concrete Clinical Example
A 45‑year‑old woman with cured Cushing syndrome (post‑surgical remission, normal cortisol) presents for follow‑up. She is a non‑smoker, BP 128/82 mmHg, total cholesterol 210 mg/dL, HDL‑C 55 mg/dL, LDL‑C 130 mg/dL, no diabetes. Pooled Cohort Equations give 10‑year ASCVD risk ≈5.2% (borderline). No family history of premature ASCVD, lipoprotein(a) 30 mg/dL, no metabolic syndrome. Lifestyle modification is advised; statin not initiated but discussed; repeat lipids in 6‑12 months.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674